| Name | Title | Contact Details |
|---|
Carta empowers hospitals to personalize the delivery of care to the individual needs of each patient. Our insight here is that personalizing care is not only good from an outcome/clinical perspective (where most people focus in the context of personalization) but is also the best way to optimize operations. Currently, hospitals have to over provision their resources because they are set up to serve the generic patient; planning ahead for exactly the resources needed– no more, no less– is the best way to gain efficiency. The approach we`re advocating and enabling is to: 1) Find past patients similar to the current one being treated 2) Quantify what exactly happened to them during their journey through the hospital (this is where our model comes in) 3) Use machine learning to project what the particular patient in question will need, and what the patient can expect their experience to be in the hospital We`re applying this approach now to two use cases– supplies projection and bed usage projection– and we have a bunch of other use cases we`re planning on addressing in the future.
Isoflux Biomed is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CleanCare Healthcare Division is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AAA Ambulance Service is a Hattiesburg, MS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Aimmune is a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. We aim to address food allergies by providing a treatment option that goes beyond the current protocols of avoiding exposure to food allergens and carrying epinephrine for administration in case of accidental exposure. Our CODIT™ system is based on extensive independent scientific research demonstrating that most patients with food allergies can become desensitized to the allergens, or proteins, in a particular food through the oral administration of gradually increasing amounts of the allergens. In oral immunotherapy (OIT), a very small amount of an allergen is administered on a daily basis and then regularly increased until desensitization to a certain amount of the allergen has been achieved. We plan to develop and commercialize standardized, pharmaceutical-grade food allergens for our CODIT™ (characterized oral desensitization immunotherapy) system, our system for OIT. Our lead product candidate, AR101, is a standardized, complex mixture of 13 naturally occurring proteins and pharmaceutical-grade ingredients that, with the CODIT system of gradual, controlled updosing and ongoing maintenance dosing, has obtained meaningful desensitization to peanut allergens in our initial clinical studies.